What We Do:
NIDA’s HIV/AIDS research grants are assigned to the Divisions within NIDA based on referral guidelines. Within each Division, there are staff with HIV/AIDS programmatic interests. Brief descriptions of their program areas and e-mail addresses are listed below. Please feel free to contact the appropriate program staff to discuss potential applications.
Division of Therapeutics and Medical Consequences of Drug Abuse
- Raul Mandler, M.D., FAAN, FANA – medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis (HCV), STDs, TB, and others; interactions between drugs of misuse and medications used in the treatment of drug addiction.
- Guifang Lao, Ph.D. – neurobehavioral processes underlying HIV risk as treatment targets; including impulsivity and risky decision-making; behavioral and integrative treatments for HIV; integration of risk reduction strategies into treatment of drug use disorders; treatments that promote adherence to HIV medications.
Division of Neuroscience and Behavior
- Roger Sorensen, Ph.D. – investigations of the neuropathology and neurological disorders caused by drug abuse and HIV/AIDS, including interactions of drugs of misuse, host and viral factors on neuronal and glial function, neuroplasticity, and the neuropathogenesis of neuronal, cognitive, and motor deficits due to drug abuse and HIV infection.
- Yu (Woody) Lin, Ph.D., M.D. – cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS; neuroinflammation; and co-morbidity; cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS and co-morbidity; biomarker development; computational science approach.
- Shang-Yi (Anne) Tsai, Ph.D. – synaptic plasticity; neuroinflammation; neuronal signaling; molecular neurobiology.
- Holly Moore, Ph.D. – cognitive, affective, and behavioral processes; behavioral models; complex morbidity involving HIV/AIDS; substance use disorders and other psychiatric disorders.
- John Satterlee, Ph.D. – molecular aspects of HIV/AIDS progression and latency and their interaction with substance abuse.
Division of Epidemiology, Services, and Prevention Research
- Peter Hartsock, Ph.D. – mathematical modeling of HIV and other infectious diseases; molecular epidemiology; international studies.
- Richard Jenkins Ph.D. – behavioral and social aspects of preventive biomedical trials; community, structural, and policy-level prevention interventions; international HIV prevention; innovative research methods and multi-method research designs; preventive intervention with men who have sex with men; prevention interventions with co-morbid populations.
- Minnjuan Flournoy Floyd, Ph.D. – organizational, systemic, and structural factors affecting/influencing delivery of HIV services cascade; social/behavioral influences of service engagement/utilization; international research/low-and middle-income countries; mixed-methods research design.
Center for Clinical Trials Network
Petra Jacobs, M.D., MHS – research at the intersection of HIV risk and substance use that includes treatment research in people living with AIDS who use substances (e.g. innovative HIV treatment, HIV and SUD treatment cascades); HIV testing and prevention among higher risk persons using drugs (e.g. new testing technologies, linkage to PrEP, long-acting PrEP); implementation research of linkage-to-care and integration-of-care models.